Cancer Conference Update 1 | 2008 - Audio Files

You are here: Home: Audio Programs: CACU 1 | 2008: CACU 1 | 2008 Audio Files


Go to individual interviews with: Stephanie A Gregory, MD Paul G Richardson, MD
To listen to individual tracks click the icon. To download tracks, right-click on the one you wish to download.

Breast Cancer


	Stephanie A Gregory, MD Professor of Medicine, Rush Medical College The Elodia Kehm Professor of Medicine Director, Section of Hematology Rush University Medical Center Chicago, Illinois Click here to download the entire interview		MP3

Track 1

Abstract 125 — PINNACLE trial: Updated analysis of a Phase II study evaluating bortezomib in patients with relapsed/refractory mantle cell lymphoma (MCL)

Track 2

Abstract 2578 — BORID trial: A Phase II study of bortezomib/rituximab/dexamethasone in relapsed/refractory MCL

Track 3

Abstract 1 — Nordic Lymphoma Group MCL2 trial: A Phase II study of intensive immunochemotherapy followed by transplantation and stem cell support

Track 4

Abstract 1362 — Overall survival among patients from a single center who were treated with CHOP-like regimens for MCL

Track 5

Abstract 385 — Phase III randomized trial of bendamustine/rituximab versus CHOP/rituximab as first-line therapy for patients with indolent or mantle cell lymphoma

Track 6

Clinical use of bendamustine in patients with indolent lymphoma

Track 7

Abstract 1351 — Phase III trial of bendamustine in patients with rituximab-refractory, indolent non-Hodgkin’s lymphoma (NHL)

Track 8

Abstract 643 — FIT: A Phase III randomized study of Zevalin^® (ibritumomab tiuxetan) consolidation versus observation after first remission in patients with advanced follicular NHL

Track 9

Abstract 1360 — Trial of fludarabine/mitoxantrone followed by Zevalin consolidation and rituximab maintenance in patients with intermediate- or high-risk follicular NHL

Track 10

Clinical use of consolidation radioimmunotherapy

Track 11

Abstract 389 — ECOG-E1499: A Phase II trial of R-CHOP followed by Zevalin consolidation in patients with untreated MCL

Track 12

Abstract 387 — SWOG-S0213: A Phase II multicenter trial evaluating hyper-CVAD and methotrexate/ ARA C with rituximab in patients with newly diagnosed MCL


	Paul G Richardson, MD Associate Professor of Medicine Harvard Medical School Clinical Director of the Jerome Lipper Center for Multiple Myeloma Dana-Farber Cancer Institute Boston, Massachusetts Click here to download the entire interview		MP3

Track 1

Overview of data presented on multiple myeloma (MM) at the 2007 American Society of Hematology (ASH) meeting

Track 2

Abstract 76 — VISTA trial: A Phase III randomized study evaluating melphalan/prednisone with or without bortezomib in patients with newly diagnosed MM who are not transplant candidates

Track 3

Toxicities associated with bortezomib in combination with melphalan/prednisone

Track 4

Clinical use of bortezomib in combination with melphalan/prednisone in patients with MM

Track 5

Abstract 450 — IFM 2005/01 trial: A Phase III study of bortezomib/dexamethasone versus vincristine/Adriamycin^® (doxorubicin)/dexamethasone (VAD) as induction therapy prior to autologous stem cell transplantation (ASCT) in patients with newly diagnosed MM

Track 6

Incidence and management of bortezomib-induced neuropathy

Track 7

Abstract 73 — GIMEMA Phase III randomized trial of thalidomide/dexamethasone (TD) versus VELCADE^® (bortezomib)/thalidomide/dexamethasone (VTD) as induction therapy prior to ASCT in patients with newly diagnosed MM

Track 8

Clinical use of bortezomib-containing regimens in patients with newly diagnosed MM

Track 9

Abstract 74 — ECOG-E4A03: A Phase III randomized trial of lenalidomide with high-dose versus low-dose dexamethasone for patients with newly diagnosed MM

Track 10

Abstract 187 — Phase I/II trial of bortezomib/lenalidomide/dexamethasone in patients with newly diagnosed MM

Track 11

Clinical use of bortezomib/lenalidomide/dexamethasone in patients with newly diagnosed MM

Track 12

Papers at ASH on management of myelodysplasia

Track 13

Papers at ASH on management of chronic myelogenous leukemia

Terms and Conditions of Use and General Disclaimer | Privacy Policy
Copyright © 2008 Research To Practice. All Rights Reserved.